2020 IDSA Guidance for Treatment of Antimicrobial-Resistant Gram-Negative Infections Deprioritizes Polymyxin Use
Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.
In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections. The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline."
Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections. He also discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.
